Nocion Therapeutics, Inc.’s Post

It is a privilege to serve as an advisor to the Lupus Research Alliance (LRA). We reviewed highly innovative and promising research proposals submitted to LRA's Translational Bridge Award program on Monday, June 10, 2024. These proposals aim to combat lupus and associated diseases, bringing promising drugs and technologies to fruition to help those in need. I look forward to collaborating with the Lupus Research Alliance and the Team again in August 2024. https://lnkd.in/gyzX8bS4 With 25+ years of expertise in drug development, due diligence, commercialization, and fundraising, I provide strategic consulting to advance innovative therapies and drive successful outcomes in the pharmaceutical and biotech sectors. #lupus #biotechnology #fundraising #pharmaceuticals #pharma #healthcare #medicine #innovation #strategy #leadership #business #success #duediligence #innoventyx

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

Civica Rx, a non-profit organization founded in 2019, is making significant strides by investing in high-quality filling systems designed to reduce the cost of life-saving medications and improve availability. Their strong patient-first focus is globally recognized and is already having a significant impact on the industry. We are fortunate to have one of Civica Rx's founders, Martin Van Trieste, as the Chair of the Board for SmartSkin, who continues to drive forward his mission to improve quality culture and prioritize patient safety across manufacturing. Read more in the following article to learn about Civica's latest developments. https://lnkd.in/e3wUAsR6

We are thrilled to be participating to CGT Founders and Funders 2024 event with Lonza on June 20th in Houston, Texas! We are honored to be part of a distinguished panel discussing innovative ways to raise funds for an IND (Investigational New Drug) application in the current environment. Our managing partner, Rich Brown, will share Plexus’ experience and perspectives in helping companies with innovative therapies and technologies articulate their value when approaching pharmaceutical players. Pitching for partnership creation and raising of non-dilutive funds goes beyond having compelling science. It requires understanding the needs of the market, capturing the essence and value of the technology, assessing the priority interests of the potential partners, and most importantly taking in account the patients’ needs. C&GT is a rapidly evolving therapeutic landscape, and Plexus Ventures is pleased to be invited by Lonza to participate in this unique event to foster dialogue and mutual understanding through interactive exercises. Event’s link: https://lnkd.in/eBakmXCe #Biotech, #CellAndGeneTherapy #Fundraising #PlexusVentures #Innovation #Healthcare #SVBLeerink #Lonza

Navigating Small-Cap Enterprises Geron Corp (GERN) is an oncology drug developer, one of whose treatments (for a type of blood cancer) received support from 12 out of 14 FDA advisory committee members in mid-March. This support suggests a potential commercial market entry and significant market presence expansion if this product is approved. Analysts predict that if these forecasts materialize, the company's revenue could increase from $0.2 million to $64.3 million over the next 12 months, with a loss per share turning into profit by the end of 2025. The FactSet consensus for GERN stock is $5.08. Learn more about investment strategies on the American stock market: https://lnkd.in/e7PZN7rm #AtraniCapital #investment #stockmarket #stockbroker #makemoney #exchange #ipo #join_ipo_deals_and_make_money #atranicapital #momentum #etf #portfolio #UHNWI #HNWI #analytics #financial #investmentportfolio #hedgefund #financialadvisor #familyoffice #investmentbank

In the August Issue of AmStat News, I highlight a new program at the American Statistical Association - the ASA Legacy Page. It's the perfect way to honor the accomplishments of the statistician or data scientist in your life. It also raises funds for important ASA programs to support the future of our profession. And it brings me great joy that Dionne Price is the first recipient of a Legacy Page made possible by generous donations given in her memory. Want to honor a colleague or loved one? Reach out to Amanda Malloy to get started. American Statistical Association - ASA, ASA Biopharmaceutical Section #statistics #datascience

Bicara Therapeutics IPO Surges Despite Challenging Biotech Market Bicara Therapeutics made a standout debut with a $362M IPO, seeing shares soar by 46% 📈. This marks a rare success in a cautious biotech IPO environment, where many recent listings have struggled to maintain their value. Bicara's bifunctional therapies for solid tumors hold great promise, positioning the company as a leader in innovation. Follow our updates to stay informed on the latest in finance and biotech news. 🌱 #IPONews #BiotechTrends #BicaraTherapeutics #FinanceUpdates #PharmaInnovation #SymptomeHR #InvestmentNews

There is nothing more important to #women than their bodies and knowledge. Our social media initiatives provide a much-needed platform for sharing this knowledge. But that knowledge comes from you—the innovators, motivators, #doctors, #nurses, associations, medical centers, #pharmaceutical companies, and surgical equipment providers. Please share what you know. This is why we don’t request donations. Your funds should go towards research and innovation, not the distribution of your message to the public. We are your travel bridge for reaching the public. Here is where you share. #anemia #pbm

Latest DON Monte Carlo news. Attention all sophisticated investors. OmniSpirant Limited are delighted to announce the granting of a Venture and Innovation Award by the UK Cystic Fibrosis Trust. OmniSpirant is currently raising funds to expand and continue to develop RNA therapeutics for diseases with high unmet medical needs. Our financial model forecasts the need to raise €80M alongside our existing non-dilutive funding to reach clinical stages and generate meaningful clinical readouts for our oncology (OS003) and ARDS (OS006) programs, both of which have potential for accelerated market approval. The funding will also be used to expand our identified pipeline (4 further programs, each capable of disrupting and expanding existing multi-billion markets), and for the scalable GMP translation of our OmniSome manufacturing process. Our versatile platform can be applied to realize significant revenues from licensing deals within the investment runway. To speak with the CEO Gerry McCauley about this opportunity please book a sophisticated investor call via this link - https://lnkd.in/ejrueCpc #funding #fundingopportunity #biotech #rnatherapeutics #rna #investing

$PYXS - Still bullish on Pyxis Oncology? Next financial report is on 9th of May 2024.: About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Pyxis Oncology was at this time reported as 2.81. The company has Price/Earnings To Growth (PEG) ratio of 0.01. Pyxis Oncology recorded a loss per share of 1.85. The entity had not issued any dividends in recent years. https://lnkd.in/e-RfXEWZ #stocks #stocktwits #thematic_portfolio